Royalty Pharma plc (OQ:RPRX)

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEC
Company Contact
Address: 110 East 59th Street
Tel: N/A
IR: See website
Key People
Pablo Legorreta
Chairman of the Board, Chief Executive Officer
Christopher D. Hite
Vice Chairman of the Board, Executive Vice President
Terrance Coyne
Chief Financial Officer, Executive Vice President
James F. Reddoch
Executive Vice President, Chief Scientific Officer
George Lloyd
Executive Vice President - Investments and General Counsel
Marshall Urist
Executive Vice President - Research and Investments
Business Overview
Royalty Pharma plc is engaged in investing in late stage biopharmaceutical products. The Company invests in academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The Company's portfolio of pharmaceutical investment includes investments in commercial products and development-stage product candidates. Its portfolio investments include AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko, Trikafta and OXLUMO.
Financial Overview
For the six months ended 30 June 2022, Royalty Pharma plc revenues decreased 3% to $1.1B. Net income decreased 30% to $356.3M. Revenues reflect Revenue from intangible royalty assets decrease of 53% to $36.1M, Income from financial royalty assets decrease of 1% to $1.03B. Net income also reflects Provision for changes in expected cash f increase from $48.5M to $290.3M (expense).
Employees: 66 as of Dec 31, 2021
Reporting Currency: U.S. Dollars
Enterprise value: $29,178M as of Jun 30, 2022
Annual revenue (TTM): $2,259M as of Jun 30, 2022
EBITDA (TTM): $1,071M as of Jun 30, 2022
Net annual income (TTM): $466.10M as of Jun 30, 2022
Free cash flow (TTM): $0.15M as of Jun 30, 2022
Net Debt Last Fiscal Year: $3,705M as of Jun 30, 2022
Shares outstanding: 607,219,969 as of Aug 1, 2022
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.